Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia

Author： Lagacé-Wiens Philippe RS  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.6, 2013-06, pp. : 789-799

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aerosolised Antibacterials for the Prevention and Treatment of Hospital-Acquired Pneumonia

By Wood G. Christopher   Swanson Joseph M.  

Drugs, Vol. 67, Iss. 6, 2007-01 ,pp. : 903-914

Adis International

Access to resources Recommend Favorite

Pharmacotherapy for hospital-acquired pneumonia

By Liapikou Adamantia   Rosales-Mayor Edmundo   Torres Antonio  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 6, 2014-04 ,pp. : 775-786

Informa Healthcare

Access to resources Recommend Favorite

Ceftobiprole medocaril is noninferior to combination therapy with ceftazidime and linezolid for nosocomial pneumonia

By  

Inpharma, Vol. 1, Iss. 1610, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Telavancin ATTAINs benefit in hospital-acquired pneumonia

By  

Inpharma, Vol. 1, Iss. 1664, 2008-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care

By Koulenti Despoina   Rello Jordi  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1555-1569

Informa Healthcare

Access to resources Recommend Favorite